Astellas Pharma Global Development
Astellas Pharma Global Development sponsors 168 registered US clinical trials on ClinicalTrials.gov, 19 of them currently recruiting, and 121 completed. 28 of these trials are in Phase 3-4 (later-stage) and 132 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 10 trials.
Trial Pipeline
168 total, page 4 of 4
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects
NCT01651325
Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects
NCT01657838
A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate
NCT02171143
Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone
NCT01597986
Drug Interaction Study of Isavuconazole and Methadone
NCT01582425
A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body
NCT01529684
Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization
NCT01565720
Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.
NCT01555866
A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects
NCT01711489
Drug Interaction Study of Isavuconazole and Digoxin
NCT01582412
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects
NCT01711827
Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240
NCT01582399
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects
NCT01809860
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
NCT02150070
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects
NCT02125435
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses
NCT01998646
Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects
NCT01565681
Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults
NCT01678287
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 105 |
| Phase 2 | 27 |
| Phase 3 | 22 |
| Phase 4 | 6 |
Therapeutic Areas
What the Pipeline for Astellas Pharma Global Development Shows
According to the ClinicalTrials.gov registry, Astellas Pharma Global Development is linked to 168 US clinical trials across every stage of research activity. Of those, 19 studies are currently recruiting, about 11% of the sponsor's indexed portfolio, and 121 are already marked complete, representing roughly 72% of the total.
The phase mix for Astellas Pharma Global Development reports 28 late-stage studies (Phase 3 and Phase 4 combined) and 132 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Astellas Pharma Global Development is Healthy Volunteers with 10 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.